Matrix metalloproteinases (MMPs) are a large subgroup of zinc-binding, multidomain endopeptidases that are present in most tissues of the body. They belong to the larger metzincin clan of metalloproteinases. In humans, there are 23 distinct MMPs comprising secreted and transmembrane proteins (BOX 1). Much of their biological activity is exerted extracellularly, where they critically influence cellular behaviour through the targeted degradation or the proteolytic processing of various extracellular matrix (ECM) molecules, peptide growth factors, cytokines, chemokines, cell adhesion molecules and many other types of receptors and glycoproteins that reside on the cell surface. The collective effects of pericellular MMP-mediated proteolysis on cell behaviour can be permissive (they can degrade chemical or physical barriers) and instructive (they can proactively initiate or terminate signalling cascades through the processing of latent bioactive molecules) 1,2 . MMPmediated remodelling of the pericellular microenvironment is therefore essential for many physiological processes. However, MMP activity can also have deleterious effects, such as in cancer, rheumatoid arthritis and other disease states 1, 3 . In the CNS, MMPs are synthesized and secreted by neurons and glia. Historically, they are associated with roles in early CNS morphogenesis 4,5 and protracted pathophysiological cellular remodelling that is triggered by injury or disease (BOX 2). Recent studies, however, show that rapid and focal MMP-mediated proteolysis proactively drives structural and functional synaptic circuit remodelling that is crucial for ongoing cognitive processes.
. In the CNS, MMPs are synthesized and secreted by neurons and glia. Historically, they are associated with roles in early CNS morphogenesis 4, 5 and protracted pathophysiological cellular remodelling that is triggered by injury or disease (BOX 2) . Recent studies, however, show that rapid and focal MMP-mediated proteolysis proactively drives structural and functional synaptic circuit remodelling that is crucial for ongoing cognitive processes.
Synaptic circuit remodelling, which includes structural alterations in the number or the morphology of dendritic spines and their synapses coupled with functional changes in the strength of synaptic signalling, occurs throughout life in naturally occurring contexts (for example, in learning [6] [7] [8] [9] ). It has become clear, largely on the basis of studies of experimentally induced forms of synaptic plasticity, such as long-term potentiation (LTP) and long-term depression (LTD), that synaptic remodelling depends crucially on a variety of ECM proteins and their receptors, cell adhesion molecules, growth factors and other targets of MMP proteolysis 10, 11 . These findings have led to a fresh outlook on the role, time course of activation and regulation of MMPs in the finescale modulation of adaptive, non-pathophysiological synaptic function and plasticity.
The goal of this Review is to capture our rapidly evolving understanding of where, when and how MMPs contribute to normal synaptic functional and structural remodelling and to speculate on the impact of perturbation of these processes in diseases that are characterized by synaptic plasticity deficits.
Metzincin
A clan of metalloproteinases comprising matrix metalloproteinases (MMPs), a disintegrin and metalloproteinases (ADAMs) and ADAMs with thrombospondin repeats. It is so-named by an amalgam of two structural hallmarks of the active site region: a conserved methioninecontaining turn downstream of -and positioned underneath to stabilize -a conserved zinc-binding motif (HExxHxxGxxH), in which the three histidine residues are zinc-binding ligands within the catalytic site. Matrix metalloproteinases (MMPs) are multidomain proteins that are named according to a sequential numbering scheme and organized into subgroups on the basis of common domains, inserts and other motifs and on the basis of shared canonical substrate preferences 1, 136, 137 . In humans, 24 MMP genes encode 23 distinct MMPs (two identical genes located on chromosome 1 encode MMP23). MMPs all possess an N-terminal signal peptide that targets them to the secretory pathway, an autoinhibitory pro-domain and a catalytic domain (see the figure). Most MMPs also possess a C-terminal haemopexin domain, which is coupled to the catalytic domain by a flexible hinge region and is an important mediator of protein-protein interactions. In cooperation with other exosites, the haemopexin domain contributes to the target specificity of MMP proteolysis by coordinating interactions with substrates. The haemopexin domain can anchor MMPs to other cell-surface proteins, thereby positioning or stabilizing MMPs at the membrane surface, which in turn markedly influences how and when MMPs become activated and regulates their accessibility to substrate targets. Additionally, MMPs can act as ligands through their haemopexin domain, activating downstream signal cascades by binding to receptors (for example, the low-density lipoprotein receptor-related protein) 138, 139 . Most MMPs are secreted into the extracellular environment. However, a minority of MMPs (seven) are membrane-associated, anchored by a type 1 transmembrane domain (MMP14, MMP15, MMP16 and MMP24), a type 2 transmembrane domain (MMP23) or a glycosylphosphatidylinositol (GPI) linkage (MMP17 and MMP25). A key feature of all MMPs is that they are synthesized as proteolytically inactive zymogens containing a pro-domain (pro-MMPs). A conserved cysteine in the pro-domain controls proteolytic activity of the enzyme by acting as a fourth zinc-coordinating ligand, rendering the catalytic site masked and inoperative when bound. Activation of MMPs requires unmasking of the catalytic site by disruption of this cysteine-zinc bond (the 'cysteine switch') 140 . For most MMPs, the cysteine switch occurs extracellularly, either through physical removal of the pro-domain via proteolytic cleavage by other extracellular proteases (for example, other MMPs or serine proteases) or by conformationally destabilizing the pro-domain via modifications of the thiol group on the inhibitory cysteine (for example, via oxidation or S-nitrosylation 69 ), which activates the MMP before subsequent proteolytic cleavage of the pro-domain. A minority of MMPs, including three secreted MMPs (MMP11, MMP21 and MMP28) and the membrane-associated ones, contain a unique sequence at the C-terminal end of the pro-domain that is recognized by the convertase furin. Thus, for most of these MMPs, the cysteine switch can occur intracellularly, allowing the release or insertion of an already proteolytically active MMP into the extracellular environment. Although MMP activity is mostly extracellular, some active MMPs can be found in neuronal or glial nuclei 141, 142 , in which they may have transcription factor-like or DNA repair-like activity 143, 144 . MMP activity is terminated in the brain mostly by four small (~22 kDa) secreted protein inhibitors called tissue inhibitors of metalloproteinases (TIMPs). The TIMPs bind reversibly to MMPs in a 1/1 stoichiometric ratio, indicating that the balance of MMP/TIMP levels determines overall proteolytic activity. Each of the four TIMP proteins displays preferential MMP-binding specificities, and also possesses biological activity independent of its role in regulating MMP activity. MT, membrane type.
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Dendritic spines
These are small actin-rich dendritic protrusions that harbour most of the excitatory glutamatergic synapses.
Gelatinases
Proteolytic enzymes that are capable of cleaving gelatin (denatured collagen). In the matrix metalloproteinase (MMP) lexicon, the gelatinases are MMP2 (gelatinase A) and MMP9 (gelatinase B), as gelatin is a canonical substrate for these MMPs.
Expression and localization in brain
Most MMPs are synthesized and secreted as inactive proenzymes (zymogens) that are converted to proteolytically active molecules following several regulatory steps
. As regulation of MMP activity can occur at the levels of transcription, translation and post-translation 1 , the levels of pro-forms and active forms of MMP and MMP proteolytic activity cannot always be inferred from MMP mRNA levels.
Biochemical experiments have shown that mRNA levels of MMP2, MMP3, MMP8, MMP9, MMP11, MMP12, MMP13, MMP14, MMP15 and MMP24 are low under basal conditions in adult human and rodent brains but are much higher during early postnatal development [12] [13] [14] [15] [16] [17] . The mRNA levels of other MMPs lie below detectable limits or have not been examined.
For some MMPs, their low transcript levels in total brain samples belie regionally higher levels of MMP mRNA expression and higher constitutive levels of protein. In adult mice and rats, increased levels of constitutive Mmp9 and Mmp24 mRNA expression are found in the hippocampus compared with other brain regions [16] [17] [18] [19] . Moreover, western blot analyses using MMP-specific antisera that recognize both the inactive pro-forms and the active forms of the enzymes, which can be distinguished by differences in their molecular mass (the pro-form is heavier than the active form), revealed that hippocampal lysates contain high levels of the proforms of MMP2, MMP3, MMP9 and MMP24 but lower levels of the active forms of these MMPs 16, [18] [19] [20] [21] [22] [23] [24] . Highresolution microscopy of immunolabelled hippocampal tissue sections showed that MMP9 is concentrated throughout the synaptic neuropile in discrete puncta that colocalize with presynaptic and postsynaptic molecular markers (FIG. 1a) , in non-synaptic dendritic regions and in some glial processes 18, 19, 21, 25 . Similarly, MMP24 has a punctate, synaptic-like distribution in perfused tissue sections of adult mouse hippocampus and cerebellum 16 . Moreover, it colocalizes with synaptic molecular markers in cultured rat hippocampal neurons and is enriched in a synaptosome fraction prepared from adult rat forebrain 23, 26 . The cellular or synaptic distributions of MMP2 and MMP3 within specific brain regions are currently unknown.
A key question raised by the data above is how much of the MMP protein is proteolytically active under basal conditions? This is a question that cannot be determined definitively by immunocytochemistry, western blotting or -for the gelatinases (that is, MMP2 and MMP9) -in gel gelatin-substrate zymography
. However, the combination of in vivo or in situ gelatin-substrate zymography (BOX 3) with immunolocalization has been used to infer the status of endogenous MMP9-mediated proteolytic activity within the synaptic neuropile 18, 27 . Through these combined approaches, a small number of the MMP9-immunopositive puncta colocalize with discrete hotspots of gelatinolytic activity that are located along hippocampal dendrites and dendritic spines. This pattern is consistent with the idea that much of the MMP9 protein detected immunocytochemically under basal conditions is in the inactive pro-form. It should be noted that these data do not rule out the possibility that other proteases that are capable of cleaving gelatin also contribute to the gelatinolytic activity observed in these experiments 21, 25 . In any event, such focal gelatinolytic puncta colocalize with molecular markers of excitatory synapses, including AMPA-and NMDA-type glutamate receptors (AMPARs and NMDARs, respectively), postsynaptic scaffolding and cytoskeletal proteins, and presynaptic vesicle proteins 18, 25 , but they seem to be largely absent from GABAergic (inhibitory) synapses 25 . In the case of MMP24, western blotting and cell-surface biotinylation assays involving cultured rat cortical neurons together indicate that although both pro-and active forms reach the cell surface, the inactive pro-form is more abundant 23 . The active form of MMP24 is only visualized on the cell surface when proteolytic activity is blocked by the broad-spectrum MMP inhibitor GM6001 (also known as ilomastat). This suggests that the duration of the active form of MMP24 on the cell surface is probably short because of proteolytic degradation, although the identity of the proteolytic enzyme responsible for surface degradation of MMP24 is unknown. Together, these data indicate that under basal conditions, high levels of MMP9 and MMP24, predominantly in their inactive pro-forms, are distributed perisynaptically at excitatory synapses that are located on dendritic spines. The observation that pro-forms of MMPs are located perisynaptically has important implications for where they exert their proteolytic effects when activated and which proteins they target (see below). Of note, various proteins that are involved in the targeting of some MMPs to synapses have been identified
MMPs drive synaptic remodelling Our emerging understanding of how MMPs contribute to normal synaptic and behavioural plasticity comes mostly from detailed studies of MMP9. The focus on MMP9 reflects the availability of a broad set of investigative reagents for this MMP and the fact that it has a well-recognized role in pathophysiological neural
Box 2 | Well-established roles of MMPs in CNS injury and disease
Excessive and protracted matrix metalloproteinase (MMP)-mediated proteolysis is a major pathological component of many CNS injuries and diseases, such as neuroinflammation, ischaemia and hypoxia, demyelination, traumatic brain and spinal cord injuries and neuronal degeneration 5, 129, 145 . A cascade of aberrant MMP activity is often initiated by MMP-mediated proteolytic degradation of the blood-brain barrier (BBB), where, for example, an ischaemic episode triggers upregulation of MMP2, MMP3, MMP7, MMP9 and MMP14 by endothelial cells, pericytes, leukocytes and other components of the neurovascular epithelium. The MMP-mediated breakdown of the BBB, which occurs over the course of 24-48 hours, allows large numbers of inflammatory and other cell types to invade the brain parenchyma, further stimulating excessive MMP expression and secretion by microglia, astrocytes and neurons. MMPs are activated by each other as well as by free radicals (such as nitric oxide), which are produced by hypoxia, thereby exacerbating a cascade of excessive MMP activity. In time, excessive MMP activity can trigger neuronal apoptosis and synapse loss. Such a cascade of excessive and essentially unregulated MMP activity within the brain parenchyma can last for weeks depending on the injury or particular insult. After this protracted destructive phase, further MMP expression can contribute to subsequent reparative processes of cell replacement, remyelination and re-establishment of connectivity and neurovascular integrity. circuit remodelling 19, 25, 28 . These new insights into the role of MMP9 in normal synaptic plasticity have been borne largely from experiments examining loss-and gain-of-function effects of MMP9 on persistent forms of synaptic structural and functional modifications such as LTP
LTP-inducing stimuli rapidly activate MMP9. Levels of both the pro-form and the active form of MMP9 are notably increased in CA1 60 min after the induction of late-phase LTP (L-LTP) at CA1 synapses by a strong tetanic stimulation protocol, and 15 min after the end of a chemical induction protocol that selectively elicits L-LTP 18, 21 . The increase in MMP9 levels induced by these L-LTP induction protocols is transient, as MMP9 levels return to baseline values by 120 min post-induction. Weaker tetanic stimulation that induces only earlyphase LTP (E-LTP), or any one of several protocols that induce LTD at CA1 synapses, does not cause any detectable changes in the levels of the pro-form or active form of MMP9 (REF. 21 ). Collectively, these observations suggest that upregulation of MMP9 is mechanistically related to L-LTP. Consistent with this idea, NMDAR antagonists and protein synthesis inhibitors abrogate the L-LTP-associated increase in protein levels 21 . The increase in MMP9 levels that results from L-LTP-inducing stimuli has been documented in both rats and mice and is consistent across ex vivo (such as acute hippocampal slices) and in vivo preparations (such as urethane-anaesthetized animals). Moreover, the increase in MMP9 levels with L-LTP is readily evident in preparations from animals of different ages (from 3 postnatal weeks to adulthood). These observations suggest that MMP9 has a fundamental role in synaptic plasticity across species and throughout life. Additionally, in terms of the gelatinases (that is, MMP2 and MMP9), L-LTP-inducing stimuli affect MMP9 levels selectively, as LTP induction has no effect on the levels of the pro-form or active form of MMP2 (REF. 21 ). Whether the levels of other MMPs are altered following the induction of LTP (or other forms of synaptic plasticity) is unknown.
Anatomical localization methods have shown that following induction of L-LTP, marked increases in the numbers of MMP9 immunoreactive puncta and gelatinolytic puncta can be seen in the neuropile of CA1 -the location of the potentiated synapses 18, 21 (FIG. 1b-d) .
Most of the LTP-associated gelatinolytic puncta colocalize with MMP9 (FIG. 1e-g ), and these puncta are found mostly at or surrounding synapses or along short stretches of dendrites. When LTP is blocked by NMDAR antagonists administered just before tetanic stimulation is used to induce LTP, the increase in the number of gelatinolytic puncta is also blocked 18 (FIG. 1b-d ). This result indicates that the appearance of gelatinolytic puncta is not a nonspecific effect of high-frequency stimulation but rather is related specifically to the LTP that results from it. Whether protein synthesis is also required to generate such L-LTP-associated hotspots of proteolytic activity has not been determined.
When these data are considered together, a striking picture emerges that indicates that MMP9 is upregulated and perisynaptically activated on a timescale (~15 min) that is roughly an order of magnitude faster than the timescales of induction and duration of MMP activity (several hours to weeks) following injury or onset of disease
. What does a proteolytically active MMP9 contribute to synaptic form and function? 
Blocking MMP9 impairs L-LTP and spine remodelling.
The contribution of MMP9 to synaptic plasticity has been investigated through acute loss-of-function (using exogenous reagents that inhibit MMP9) and chronic loss-of-function (using genetic deletion) experimental approaches. Field recordings in CA1 show that L-LTPinducing stimuli applied to the Schaffer collaterals in the presence of pharmacological MMP inhibitors or MMP9-specific neutralizing antibodies induce LTP at CA1 synapses that is indistinguishable from that induced in controls (by L-LTP-inducing stimuli applied without inhibitors) for 30-45 min but which then declines rapidly to baseline values 18, 21, 29, 30 . This suggests that MMP9 inhibitors have no effect on E-LTP but block L-LTP selectively.
The contribution of MMP9 activity to the spine enlargement that accompanies persistent LTP has been examined by combining whole-cell recordings from CA1 pyramidal cells with simultaneous twophoton imaging of their dendritic spines 29 . In a thetaburst stimulation paradigm applied in the presence of MMP inhibitors, spine enlargement and LTP were both induced normally but both subsequently collapsed to baseline, which is consistent with the time course of the effects of the inhibitors observed in the field recording experiments discussed above. The impaired stability of both LTP and spine structural plasticity was evident only when inhibitors were applied for a period of up to ~30 min post-induction; when they were applied after this point, L-LTP and spine enlargement were resistant to decay and therefore MMP9-independent effects. These observations suggest that MMP9 contributes to a consolidation-like process during the first 30 min of LTP in which coordinated functional and structural plasticity becomes stable and immutable. Similar time-dependent effects of pharmacological MMP inhibitors on LTP persistence have been described for synapses in other hippocampal circuits 31 and in other brain regions, including the amygdala 5 and prefrontal cortex 32 . Interestingly, the acute MMP inhibitors that interfere with LTP persistence have no effect on the magnitude or time course of paired-pulse facilitation (PPF), which is a form of presynaptic plasticity. These inhibitors also have no effect on E-LTP that is induced by weaker tetanic stimulation protocols or on NMDAR-dependent or metabotropic glutamate receptor (mGluR)-dependent forms of LTD. Thus, MMP9 seems to have a specific role in the persistence of L-LTP, which is consistent with the lack of upregulation or activation of MMP9 in response to LTD, PPF or E-LTP, as discussed above. MMP inhibitors also have no effects on the baseline properties of synaptic neurotransmission, spine size or spine morphology, which suggests that MMPs become operative only under the demands of dynamic synaptic remodelling and is consistent with the observation that much of the MMP9 present within the neuropile under basal conditions is in the inactive pro-form. This notion stands in contrast to a recent study showing that members of the ADAM (a disintegrin and metalloproteinase) family of metalloproteinases may have a constitutive role in regulating baseline levels of synaptic neurotransmission, at least in cultured neurons 26 . The lack of any direct involvement of MMP9 in hippocampal baseline neurotransmission, PPF or LTD is also supported by studies of MMP9-deficient (Mmp9 −/− ) mice, in which none of these processes is affected by the absence of this MMP 21 . However, results from other studies using broad-spectrum metalloproteinase inhibitors (FN439 and GM6001) suggest that other metalloproteinases (that is, other MMPs or ADAMs) may contribute to these forms of plasticity. In one study, hippocampal slices that were exposed to FN439 exhibited deficits in both PPF and LTD 30 . Speculatively, deficits in PPF might arise through FN439-mediated inhibition of MMP7, as exogenous application of active MMP7 impairs synaptic vesicle release and uptake dynamics 33 , possibly through intracellular cleavage of synaptic vesicle proteins 34 . Similarly, diminished presynaptic vesicle release has also been reported following long-term (overnight) exposure of hippocampal cultures to GM6001 (REF. 26 ). Deficits in LTD could arise if broad-spectrum pharmacological blockers affected the activity of ADAM17 (also known as TACE), as this enzyme is required for mGluR-dependent LTD 35 . Two studies have reported that nonspecific MMP inhibitors impair LTP induction in CA1 (REFS 30, 36) , which is in contrast to the data discussed above that suggest that MMP9 does not contribute to LTP induction. As most MMP inhibitors lack selectivity, it is possible that such discrepant results reflect off-target effects of
Box 3 | Gelatin-substrate zymography techniques
In gel gelatin-substrate zymography This is an SDS-PAGE-based technique for the detection of enzyme activity based on the ability of the enzyme to cleave a substrate (gelatin) that is co-polymerized with the polyacrylamide gel. The advantages of this technique are that it is sensitive enough to detect picogram levels of an enzyme and it can resolve pro-forms and active forms of gelatin-cleaving matrix metalloproteinases (MMPs; for example, MMP2 and MMP9) on the basis of their molecular mass. The disadvantages are that it lacks cellular resolution, is not applicable to non-gelatinolytic proteases and does not accurately report on endogenous enzyme activity because of some auto-activation within the gel and the loss of any endogenous tissue inhibitor of metalloproteinases (TIMP)-binding during preparation.
In situ gelatin-substrate zymography This is a technique for visualizing gelatinolytic enzyme activity within semi-intact tissues or cells. The approach is to expose acute tissue slices or cell cultures to dye-quenched (DQ)-gelatin, which is gelatin coupled to a fluorescent molecule (fluorescein) that is masked until it is cleaved. Upon cleavage by endogenous gelatinases, the fluorescein becomes visible and, after aldehyde fixation, it can be detected by fluorescent microscopy. The advantages of this approach are that it provides cellular and synaptic anatomical resolution of endogenase gelatinolytic enzymes and can be combined with immunolocalization of other proteins of interest. The disadvantage is that it requires numerous controls to show that enzyme activity is not altered as a result of tissue slicing or other processing steps before visualization.
In vivo gelatin-substrate zymography
This technique is an extension of in situ gelatin-substrate zymography. However, in this case, the DQ-gelatin is injected directly into the brain of an intact animal in vivo. The animal is subsequently perfused with aldehydes and the fluorescent gelatinolytic puncta can be visualized by fluorescent microscopy. The advantage of this approach, in addition to those of in situ zymography, is that brains are not sliced before the gelatinolytic reaction, thereby eliminating the potentially confounding effects of the processing steps on enzymatic activity.
Integrins
Heterodimers composed of an α-and a β-subunit. In mammals, there are 18 α-and eight β-subunits. They are canonical receptors of extracellular matrix and other proteins. In hippocampus, most integrin heterodimers contain the β1-subunit.
Cofilin
This is an actin-binding protein that is enriched in dendritic spines. Cofilin is a member of the ADF (actin-depolymerizing factor)-cofilin family and regulates the disassembly of filamentous actin. Cofilin is negatively regulated by phosphorylation at a single site (Ser3). −/− mice restores normal levels of LTP could reflect an MMP9-dependent enhancement of synaptic neurotransmission (discussed below).
SNARE
MMP9 activation proactively drives synaptic remodelling.
Although loss-of-function approaches indicate that MMP9 is necessary for the persistence of functional and structural synaptic plasticity, acute gain-of-function experiments conducted in slices or in vivo show that MMP9 is also sufficient for driving functional and structural synaptic remodelling in the absence of conventional LTP-inducing stimuli 21, 29 . Brief, local application of proteolytically active MMP9 to unstimulated dendritic spines of CA1 pyramidal neurons induces an LTP-like increase in synaptic signal strength and concurrent spine enlargement, both of which reach a maximum in the 15-20 min period after the spines are first exposed to the enzyme. Such plasticity is not observed when spines are exposed to pro-MMP9. Moreover, spines and synapses are unresponsive to active MMP2. Functional and structural plasticity induced by MMP9 depends on signalling through β1 subunitcontaining integrins, and is associated with integrindependent phosphorylation (and hence inactivation) of the actin-depolymerizing factor cofilin within dendritic spines. Additionally, such MMP9-induced synaptic and spine plasticity occludes subsequent potentiation and spine enlargement that are induced by theta-burst or tetanic stimulation 18, 29 , which suggests that common mechanisms of synaptic potentiation and spine remodelling are shared by MMP9 and electrical stimulation protocols. Consistent with this suggestion, MMP9-induced potentiation and persistent spine enlargement are both sensitive to inhibitors of protein synthesis as well as reagents that interfere with postsynaptic actin polymerization and blockers of SNARE-dependent exocytocis in postsynaptic neurons 29 . Such sensitivity to these reagents is identical to those of electrically evoked LTP and spine plasticity 38 . Together, these findings support a working model of the molecular cascade of MMP9 activity in driving synaptic remodelling: from MMP9 activation by LTP induction to its downstream target effects driving persistent potentiation. According to this model (FIG. 2) , perisynaptic pro-MMP9 is rapidly activated by NMDAR-mediated signalling that occurs during LTP induction. Active MMP9 then signals, via proteolysis of an as-yet-unidentified target (see section below for candidates), through β1-containing integrins on dendritic spines 39 to couple actin-dependent structural changes in spine shape with actin-dependent functional changes in synaptic neurotransmission.
Integrins are crucial for the consolidation of LTP 40, 41 ; they activate downstream signalling cascades that increase synaptic glutamate receptor-mediated currents 42, 43 , regulate surface expression and composition of AMPARs 44 and promote spine actin polymerization 45, 46 . Persistence of LTP requires the insertion of AMPARs into the synaptic membrane 38, 47 , which in turn stabilizes LTPassociated spine enlargement 38, 48 . Consequently, it seems that MMP9-mediated potentiation of synaptic transmission ultimately arises from integrin-directed trafficking of AMPARs into the synaptic membrane, which in turn stabilizes the spine enlargement, thereby consolidating both forms of MMP9-driven plasticity (FIG. 2) .
In contrast to the potentiating and spine-enlarging effects of local, transient MMP9 exposure, widespread and chronic application of active MMP9 produces seemingly opposing effects, at least on spine morphology. In dissociated hippocampal cell or organotypical slice cultures, active MMP9 that is bath-applied for up to 90 min induces the production of long, thin dendritic spines with smaller spine-heads 24, 49 , which represents an immature spine morphology. Additionally, although bath-applied MMP9 has no apparent effects on synaptic physiology for the first 90 min of exposure, after this point miniature excitatory postsynaptic currents (mEPSCs) display longer deactivation time constants. Other studies involving cultured neurons have revealed that active MMP9 increases the lateral mobility 50 and desensitization kinetics 51 of surface NMDARs without
Box 4 | How are MMPs directed to or near synapses?
Recent studies show that AMPA receptor (AMPAR)-binding protein (ABP) and glutamate receptor-interacting protein 1 (GRIP1), two postsynaptic scaffolding proteins that bind to and direct AMPAR subunits to the synaptic membrane 146 , also bind to the C-terminal tail of matrix metalloproteinase 24 (MMP24), which is a transmembrane protein, and direct it to synaptic sites 23 . In the case of secreted MMPs, the basis for such synaptic targeting is less well understood. Image analysis of intracellular trafficking of MMP2, MMP9 or the endogenous MMP inhibitor tissue inhibitor of metalloproteinases 1 (TIMP1) fused to green fluorescent protein expressed in cultured hippocampal neurons 147 and glia 141 shows that these MMPs and TIMP1 are transported in distinct 160-200 nm-wide vesicles that, for neurons, are concentrated in the somatodendritic domain. Interestingly, although TIMP1 is colocalized in vesicles carrying either MMP2 or MMP9, these two MMPs are distributed into separate vesicle populations in both neurons and astrocytes, which suggests that there is differential control of their trafficking and release. Such vesicles associate with cytoskeletal components and the molecular motors dynein, kinesin and myosin Va, are found in dendritic spines and can be secreted as exosomes from these sites 147 . In non-neuronal cells, release of such MMP-containing vesicles depends on proteins of the SNARE family 148 , although it is unclear at present whether regulated release in neurons occurs by a similar mechanism. Additionally, whether non-vesicular release of soluble MMPs or TIMPs occurs in neurons or glia also remains to be explored.
having any effects on surface mobility of AMPARs. This observation is interesting in light of the fact that enzymatic degradation of the ECM that normally surrounds neurons and synapses increases the surface mobility of AMPARs but not that of NMDARs 52 . These differences in glutamate receptor-subtype mobility following degradation of the ECM may indicate that the loss of the ECM is permissive for AMPAR mobility, whereas NMDAR mobility may be regulated selectively by an MMP9-mediated mechanism. Indeed, although the precise relationships between the altered kinetics of synaptic and NMDAR-mediated currents, the increased rates of NMDAR diffusion and the transition towards an immature spine morphology that are observed in cultures are presently uncertain, all of these MMP9-linked effects in neuronal cultures are dependent on β1-containing integrins.
Such stark differences in MMP9-driven, β1-integrindependent effects on synaptic form and function between the different gain-of-function experimental approaches might be attributed to the nature and time course of MMP9 application. Global exposure of an entire network of cultured neurons to an active MMP could generate homeostatic adjustments in synaptic currents or spine morphology that differ substantially from local and delimited effects on a small subset of spines 53 , as all neurons and their synapses would be affected simultaneously during bath-exposure to the active MMP. Indeed, bathapplication of MMP7 to dissociated hippocampal cultures also results in a transition from mature to immaturelooking spines, global increases in the phosphorylation of the NMDAR subunits NR2A and NR2B 54 , and in the ectodomain cleavage of NMDAR subunits NR1 and NR2A 55 . An increasingly more widespread exposure to active MMPs, coupled with long exposure times, may underlie how MMPs transition from adaptive, acute mediators of local synaptic remodelling to maladaptive, deleterious effectors of aberrant synaptic and neuronal networks (FIG. 3) . Indeed, transgenic rats that constitutively overexpress an autocatalytically active form of MMP9 not only possess hippocampal neurons with immature-looking spines but also exhibit a lower threshold for epileptogenesis 25 , which suggests that global and/or chronic MMP activity contributes to a pathophysiological profile of cellular and synaptic architecture.
It should be noted that the different states of neuronal development represented by culture models versus intact circuitry of adult hippocampus in vivo or in acute ex vivo slices could also contribute to different outcomes of MMP9-driven integrin activation. Direct activation of integrins on young cultured neurons produces spine elongation and decreased filamentous actin content within dendritic protrusions 56 , whereas integrin activation in mature, intact circuitry drives actin polymerization in spine-heads and is associated with spine enlargement 45 . In addition, important differences between model systems in the extracellular milieu may also be relevant to different outcomes, as some of the MMP7-mediated effects on neurons in culture vary depending on the substrate upon which the neurons are grown 54 .
MMPs contribute to behavioural and experiencedependent plasticity. The mounting evidence indicating that MMPs are a necessary component of the molecular mechanisms that couple and consolidate synaptic functional and structural synaptic remodelling suggests that MMP activity would also influence cognitive tasks that depend on such synaptic plasticity. This is indeed the case, as several associative and non-associative learning and memory paradigms -which were conducted in conjunction with in vivo delivery of pharmacological blockers or MMP antisense oligonucleotides, or with MMP overexpression models -have shown that MMPs, particularly MMP3 and MMP9, have important roles in cognitive performance 20, 21, [57] [58] [59] [60] [61] . Inhibitory avoidance (IA) learning, which is a singletrial fear conditioning type of learning and memory task 62 that elicits an LTP-like increase in the strength of synaptic transmission in CA1 (REF. 63 ), leads to markedly increased levels of both pro-forms and active forms of MMP3 (REF. 60 ) and MMP9 (REF. 20 ). In the case of MMP9, the increase in levels of the active form is matched by increased gelatinolytic activity: both are markedly higher 6 hours after IA training and remain raised for ~48 hours. Importantly, such upregulation is not evident following exposure to either the chamber (the context) or the aversive stimulus (the shock) alone but only when these two are coupled in time. Functionally, blockade
Box 5 | Hippocampal long-term potentiation
Hippocampal long-term potentiation (LTP) is the archetypal cellular model of synaptic functional and structural plasticity that enables memory formation 63 , information processing 149 and skill learning 150 . Tetanic or theta-burst stimulation protocols applied to the Schaffer collaterals (axons of CA3 pyramidal neurons) elicit NMDA receptor (NMDAR)-dependent LTP at CA3-CA1 glutamatergic synapses, which are located mostly on dendritic spines. At these synapses, LTP reflects functional changes in the magnitude of synaptic neurotransmission that are coordinated with structural changes in synaptic spine morphology, size and density 151 . Functionally, LTP has at least two mechanistically distinct phases, the occurrence of which depends on the strength of the induction protocol. Weak stimulation protocols elicit so-called early-phase LTP (E-LTP), which is transient and involves post-translational modifications of synaptic proteins but is protein synthesis-independent. By contrast, stronger, repetitive stimulation protocols elicit E-LTP followed by late-phase LTP (L-LTP), which is protein synthesis-dependent and persistent 152 . In L-LTP, spines undergo actin-dependent increases in spine-head volume, changes in density and enlargement of synapses. These phenomena are all thought to be important structural correlates of stable changes in synaptic strength 153 . LTP and the accompanying dendritic spine plasticity, particularly those evoked by theta-burst stimulation, which mimics endogenous patterns of neural activity during learning 154 , are initially labile and subject to reversal by a number of protocols before transitioning, via a consolidation-like process, to a stable form that is resistant to reversal protocols 155 . Nature Reviews | Neuroscience of MMP activity with intrahippocampal administration of pharmacological blockers or MMP9-specific neutralizing antisera starting ~3 hours after IA training, just before the onset of training-induced MMP activity, completely abrogates memory for the IA response when tested days later. These data, when allied with the emerging understanding of how MMPs contribute at the cellular and molecular levels to synapse and spine remodelling, suggest that learning induces a period of focal MMP-mediated proteolysis that is vital for driving long-lasting synaptic modifications of the kind that underlie memory consolidation. Considerable synaptic remodelling also occurs during rapid-eye movement (REM) sleep 64 , and recent studies suggest that MMPs may be involved in this remodelling process. Sleep deprivation in rats is associated with diminished levels of Mmp9 mRNA in cortical structures 65 , and treatment of sleep-deprived rats with modafinil, a wakepromoting pharmacological reagent that is used to treat narcolepsy, increases Mmp9 mRNA levels and restores cognitive function of sleep-deprived animals 66 . Lastly, recent in vivo studies of visual 67 and somatosensory (barrel) cortex 68 suggest that MMPs facilitate functional and structural changes in connectivity that underlie experience-dependent alterations in representational maps.
Together, the data discussed above indicate that MMPs have an active role in remodelling synaptic structure and function during LTP, a role that is crucial for cognitive and sensory function. This raises important questions about how the onset and termination of MMP activity is coupled to LTP and the target molecules through which MMPs influence synaptic form and function.
Time course and targets of MMP activity
There are several distinct mechanisms that could activate, sustain and terminate perisynaptic MMP proteolysis following LTP induction. Although the precise onset of proteolysis relative to the onset of LTP induction remains to be definitively determined, in principle, the latent, perisynaptic pool of pro-MMPs could be activated quickly by molecules that are capable of converting pro-MMPs to their active forms and are rapidly released by LTP induction. One attractive candidate molecule is nitric oxide (NO), a gaseous, diffusible cellular messenger. NO can activate MMP9 (REFS 69, 70) , is released from postsynaptic neurons by theta-burst-stimulated LTP in an NMDAR-dependent manner and contributes to L-LTP 71 . Additionally, the release of NO is presumably localized to potentiated synapses, in which it could activate MMP proteolysis locally (FIG. 2) . MMP9 can also be activated by the serine protease tissue plasminogen activator (tPA) in some cell types 72 . tPA is encoded by an immediate early gene that is rapidly upregulated by LTP induction 73 ; tPA is then released from dendritic spines 74 . However, the gain-of-function effects of tPA on neuronal activity and morphology are markedly different to those induced by MMP9 (REF. 75 ). When applied to hippocampal slices, active tPA converts a normally transient potentiation induced by a weak stimulus protocol into persistent LTP but does not, by itself, induce synaptic potentiation. Moreover, in cultured neurons, tPA increases axon growth and the formation of presynaptic boutons. These different effects on synaptic plasticity and morphology in comparison with those described above for active MMP9 make it unlikely that tPA is immediately upstream of MMP9 in the context of LTP-triggered proteolytic remodelling. Instead, such differences suggest that tPA, MMPs and other LTPactivated extracellular proteases 76,77 operate along largely independent pathways but act synergistically to remodel the synaptic microenvironment. Once pro-MMPs are activated at the synapse following LTP induction, new MMP synthesis and secretion probably replenishes the pro-MMP pool, as the LTPtriggered increase in MMP9 levels is sensitive to protein 155 and behaviourally induced 63 forms of synaptic plasticity affect a minority of synapses that are widely distributed. Thus, during long-term potentiation (LTP; red zig-zags), matrix metalloproteinases (MMPs) are activated locally at a minority of synapses distributed widely throughout the neuropile. Ab | Within ~15 min, active MMP9 coordinately drives dendritic spine enlargement (arrow) and potentiation as part of an integrin-dependent consolidation process. Ac | After 1-2 hours, MMP activity is terminated, most likely by increased tissue inhibitor of metalloproteinases (TIMP) activity. Ba | By contrast, under pathophysiological conditions, ischaemic or inflammatory disruption of the blood-brain barrier results initially from aberrant expression of a number of MMPs within the neurovascular unit. Such MMP-mediated activity leads to subsequent invasion into the brain parenchyma of inflammatory and other cell types. Bb | This in turn triggers further aberrant MMP expression and secretion by astrocytes, neurons and microglia. Under these conditions, MMPs are activated by each other and by free radicals such as nitric oxide. Such excessive and active MMPs then infiltrate networks of neurons and their synapses. Bc | Broad and sustained MMP exposure at all or most synapses of a network lead to conversion of dendritic spines to immature-like filopodia, followed by synapse breakdown and, eventually, neuronal apoptosis.
synthesis inhibitors (discussed above). Studies suggested that Mmp9 mRNA is localized to dendrites and dendritic spines of granule cells in rat dentate gyrus. Moreover, 12-24 hours following kainate-induced epileptogenesis in rats, levels of Mmp9 mRNA increased within the molecular (dendritic) layer of the dentate gyrus, which is attributed to both dendritic and glial expression 19, 78 . Similarly, increases in Mmp9 mRNA levels have been detected in the hippocampus 2 hours post-seizure onset following administration of the GABA A receptor antagonist pentylenetetrazole 79 . Together, these findings suggest that Mmp9 mRNA could be translocated into dendrites and locally translated at synaptic sites under activitydependent conditions. However, in CA1, there is no evidence yet for increased levels of Mmp9 mRNA, either in somata or dendrites, at 75 min following LTP induction by strong tetanic stimuli delivered in vivo 18 . Thus, LTPrelated transcriptional regulation probably occurs at later time points when it might serve to sustain MMP activity levels. More studies are required to characterize potential transcriptional regulation of MMPs in the context of LTP.
Behaviourally, the upregulation in MMP9 levels following IA training 20 probably results from increases in translation and transcription. The Mmp9 promoter contains binding sites for the transcription factor nuclear factor-κB (NF-κB) 80 , and IA training increases the transcriptional activity of NF-κB during the period over which MMP9 levels rise 81 . Other studies 79 suggest that Mmp9 mRNA synthesis in neurons is subject to epigenetic regulation of the transcriptional repressor YY1, whereas under conditions of epileptogenesis, transcriptional regulation of mRNAs encoding MMP9 or tissue inhibitor of metalloproteinases 1 (TIMP1) may be controlled by the transcription factor activator protein 1 (AP1; also known as JUN) 82, 83 . At the translational level, recent studies implicate microRNA-dependent control of MMP9 levels 84 . An important goal is to determine how these various transcriptional and translational mechanisms contribute to MMP-driven modulation of synaptic or behavioural plasticity.
It also remains to be determined precisely how focal MMP-mediated proteolysis is terminated following synaptic remodelling. TIMPs are likely to be key regulators of this termination step (FIG. 2) , as Timp1 mRNAs are rapidly upregulated following LTP induction or epileptogenesis in the hippocampus 85, 86 . Importantly, viral-mediated TIMP1 overexpression in the rat prefrontal cortex (PFC) abolishes the persistence but not the induction of LTP at subiculum-PFC synapses 32 . Behaviourally, the results of several studies, using a variety of approaches to interfere with or augment TIMP activity, are consistent with the idea that TIMPs are critical modulators of MMP activity that is necessary for the performance of a variety of behaviours, including olfactory learning 87, 88 , pre-pulse inhibition of the startle reflex 89 , spatial navigation in a water maze and habituation in an open field 90 .
Targets of MMP proteolysis underlying synaptic remodelling. Several molecules have been identified or suggested to be MMP targets through which MMP-mediated proteolysi s contributes to synaptic remodelling.
The involvement of integrins as mediators of almost all aspects of MMP9-driven forms of synapse and spine plasticity discovered to date casts the spotlight on endogenous integrin ligands as MMP proteolytic targets that drive synaptic remodelling. In this context, recent studies show that intercellular adhesion molecule 5 (ICAM5; also known as telencephalin) may be an important MMP target. ICAM5 is a transmembrane protein that is a member of the immunoglobulin superfamily and binds to and activates integrins in the immune system 91 .
In the brain, ICAM5 localizes to dendrites and filopodia 92 , in which it negatively regulates spine number and maturation during development 93 . Recent studies show that LTP-inducing tetanic stimulation of CA1 synapses promotes MMP-dependent shedding of an N-terminal ectodomain fragment of ICAM5 that is detectable 15 min after LTP induction 36 (FIG. 2) . Such cleavage can be mimicked by exposing cultured neurons to NMDA and can be blocked by the application of MMP inhibitors 36, 94 , which is consistent with the idea that NMDARs are upstream of MMP activation as discussed above. Similarly, active forms of MMP3, MMP7 and MMP9 can promote ICAM5 ectodomain shedding in cultured neurons 36 . Biochemical studies demonstrate that the cleaved ICAM5 fragment associates with β1-integrins, and when applied to cultured neurons, it stimulates β1-integrindependent phosphorylation of cofilin 95 . Members of the cadherin family of cell adhesion molecules are also targets of MMP-mediated perisynaptic proteolysis. MMP-dependent ectodomain cleavage of neuronal (N)-and epithelial (E)-cadherin has been demonstrated in several cell types, including cultured neurons 96 , and may reflect the activity of MMP24 (REF. 23 ). Nevertheless, it is not clear at present how MMP-mediated processing of synaptic cadherins would contribute to LTP and associated spine enlargement, as L-LTP-inducing stimuli promote N-cadherin synthesis and recruitment to synapses 97 , in which it has a vital function in stabilizing both LTP and spine enlargement in CA1 neurons [97] [98] [99] . One possibility is that such MMPmediated proteolysis may affect only a subset of cadherin molecules, perhaps ones that are highly localized to a particular synaptic or perisynaptic domain.
Another activity-dependent target of MMPs that has been identified in neuronal culture assays is β-dystroglycan 100 . This molecule is a transmembrane protein that, together with α-dystroglycan, couples the ECM to the actin cytoskeleton 101 . The onset of seizure activity in hippocampus increases the levels of a proteolytic fragment of β-dystroglycan, but this fragment is absent in Mmp9 −/− mice 100 . These data suggest that such cleavage is MMP9-dependent and occurs in an activity-dependent manner under pathophysiological conditions. Whether such MMP-directed proteolysis of β-dystroglycan contributes to synaptic remodelling in non-pathophysiologica l or other contexts has not been studied.
Several studies indicate that myelin-associated, axon growth-inhibitory molecules (that is, MAG (myelin-associated glycoprotein), NOGO66 (neurite outgrowth inhibitor 66; also known as RTN4) and OMGP (oligodendrocyte myelin glycoprotein)) and one of their associated receptors, NGR1 (NOGO66 receptor 1; also known as RTN4R), are important in gating the expression of ocular dominance plasticity in the visual cortex 102 , and LTP and spine plasticity in the hippocampus 103 . Cell culture assays demonstrate that MAG can be cleaved by MMP2, MMP7 or MMP9, releasing bioactive fragments that inhibit axonal outgrowth from dorsal root ganglion neurons 104 . Similarly, NGR1 can be cleaved by MMP14, MMP15, MMP16 or MMP24, which diminishes growthcone collapse in response to myelin-associated inhibitors 105 . Interestingly, the cleaved ectodomain fragment of NGR1 retains the ability to bind NOGO66, suggesting it can act as a dominant-negative entity under physiological conditions 105 . These data suggest that MMP-mediated proteolytic regulation of this inhibitory signalling system directly influences the molecular cascade through which myelin-derived inhibitors and their receptors regulate experience-dependent synaptic plasticity.
Members of the family of insulin-like growth factors (IGFs) and their related receptors and binding proteins have recently been implicated in the molecular mechanisms underlying memory consolidation 106 , and some of these are targets of MMP-mediated proteolysis. Levels of IGF2 mRNA and protein are upregulated in the rat hippocampus 20 hours after IA training 107 . Antisensemediated knockdown of IGF2 or its interacting IGF2 receptor (IGF2R) markedly impairs IA memory retention, whereas administration of exogenous IGF2 promotes persistent hippocampal LTP. In other systems, the bioavailability of IGF2 is regulated by sequestration through binding to insulin-like growth factor binding protein 2 (IGFBP2) 108 . Studies show that the IGF2-IGFBP2 complex is proteolytically processed by MMP9 (REF. 109 ), thereby releasing IGF2 for full bioactivity. Notably, MMP9 upregulation by IA training coincides with the period over which IGF2 is operative in memory consolidation, which raises the possibility that MMP9 critically regulates bioavailability pool of IGF2 as part of an orchestrated sequence of molecular mechanisms that consolidate and enhance memory.
Lastly, in addition to the candidate MMP targets described above, there is a growing list of additional molecules with documented roles in synapse development, plasticity and function that are also known targets of MMPs 110 . These include: tenascins; synaptogenic proteins such as the thrombospondins, hevin and SPARC; neurotrophins; tumour necrosis factor-α (TNFα); and ephrins and their eph receptors. Whether MMPmediated processing of these molecules contributes to synaptic remodelling during LTP or in any other context remains to be rigorously tested.
MMP proteolysis in brain disorders
It is increasingly recognized that several neurological and psychiatric brain disorders have deficient or maladaptive synaptic functional and structural plasticity at their core [111] [112] [113] [114] [115] . Fast, focal MMP-mediated perisynaptic proteolysis is a crucial driver of ongoing, adaptive synaptic remodelling that has direct consequences on behavioural plasticity, and the recognition of this has led to the establishment of a new conceptual framework for linking MMP-mediated proteolysis to pathophysiological, maladaptive synaptic remodelling. Some recent studies that examine the relationship between MMP activity and potentially maladaptive synaptic remodelling capture these emerging links and are briefly highlighted here.
In rodent models, repeated exposure to the illicit psychostimulant methamphetamine is associated with persistent abnormalities in the density and morphology of dendrites and spines 116 and alterations in LTP 117 in a number of forebrain structures. Protein and mRNA levels of MMP2, MMP9 and TIMP2 are increased in the rat prefrontal cortex, nucleus accumbens and hippocampus following repeated methamphetamine exposure 95, 118 , whereas abrogating MMP expression or function blocks behavioural sensitization to methamphetamine 119 . Moreover, the reinstatement of cocaine-induced conditioned place preference (CPP) by cocaine-priming is associated with increased expression and activity of MMP9 in the rat medial prefrontal cortex 120 , and blocking such MMP9 activity impairs acquisition of cocaine-induced CPP or subsequent reinstatement of CPP upon cocainepriming 121 . Mechanistically, acute methamphetaminetreatment in vivo stimulates cleavage of ICAM5 in the striatum and hippocampus by ~6 hours post-treatment; such methamphetamine-induced cleavage is blocked by MMP inhibitors when it is recapitulated in vitro 95 . Additionally, the expression and activity levels of β1-and β3-containing integrins -critical signalling mediators of MMP9 remodelling as well as of ICAM5 activity -are bidirectionally regulated by cocaine treatment, withdrawal and relapse in the nucleus accumbens 122 . Additionally, exposure to morphine drives aberrant MMP9 activity in neurons and glia in the spinal cord dorsal horn, whereas inhibiting MMP9 blocks morphine dependence 70 . As persistent drug craving resembles dysfunctional synaptic plasticity processes that are involved in memory consolidation 111 , these studies together suggest that drugs of abuse co-opt normal, ongoing and adaptive MMP-mediated synaptic plasticity by driving maladaptive MMP expression, circuit remodelling and addictive behaviour.
Neuropathic pain is also associated with aberrant synaptic circuit rewiring in the spinal cord 113 . Following ligation of the fifth lumbar spinal nerve -a standard rodent model for neuropathic pain -levels of MMP9 are rapidly but transiently raised in injured dorsal root ganglion neurons, whereas upregulation of MMP2 occurs at later time points, which suggests a role for these different MMPs in different phases of neuropathic pain 123 . Consistent with this, suppression of MMP9 inhibits the initial phase of aberrant pain sensation but suppression of MMP2 inhibits persistence. Intrathecal delivery of active MMP2 or MMP9 delivery causes behavioural changes that mimic behavioural manifestations of neuropathic pain. The MMP-driven effects may be mediated through proteolytic processing of the proinflammatory cytokine interleukin-1β 123 . Fragile X syndrome (FXS) is the most common inherited form of intellectual disability and autism 124 , and is caused by a trinucleotide expansion that inactivates the fragile X mental retardation 1 (FMR1) gene, leading to the loss of fragile X mental retardation protein (FMRP). FMRP is a postsynaptically localized RNA-binding protein that regulates local translation of a select subset of mRNAs at synapses 125 . One abnormal structural hallmark of humans and mice lacking FMRP is an overabundance of long, thin, immature-appearing dendritic spines with corresponding defects in synaptic and experience-dependent plasticity 126 . The spine structural abnormalities associated with FXS are very similar to those described above following global and prolonged MMP9 exposure in hippocampal cultures, which suggests that aberrant expression, localization and/or activity of MMP9 could contribute to spine and plasticity deficits in FXS. Indeed, recent studies show that levels of MMP9 as well as gelatinolytic activity are both increased in hippocampal lysates from Fmr1 −/− mice in comparison with those from wild-type mice 24 . Importantly, treatment of Fmr1 −/− mice with minocycline, a tetracyline derivative that -among many of its targets -blocks MMP9 activity 127 , reduced levels of endogenous MMP9 activity, reversed the abnormal behaviours that these mice display and restored dendritic spines to normal morphologies 24 . These findings have recently been largely validated in a Drosophila melanogaster model of FXS 128 . Together, these data indicate that a strong correlation exists between aberrant MMP9 function and abnormal spine-and circuit-level architecture in FXS, and potentially offers a realistic therapeutic approach to reversing dendritic spine, circuit and behavioural abnormalities that are driven by excessive MMP proteolysis.
Conclusions and perspective
MMPs can no longer be regarded solely as injury-related molecules in the mature nervous system. Multiple and compelling lines of evidence now show that MMPs are vital molecular drivers of synaptic structural and functional remodelling of the kind that supports ongoing cognitive functions.
One important area for future investigation is to determine precisely how MMP activity transitions from its normal, adaptive roles in synaptic circuit remodelling to its aberrant and deleterious roles that have important pathophysiological cellular and synaptic consequences. At its core, the transition in MMP-mediated cellular responses is probably dictated by the relative scale in amount, duration and spatial extent of MMP activity. In the case of disease or injury, this scale is potentially quite large (FIG. 3) . Neurons, glia and a variety of invading inflammatory cell types all contribute to a massive increase in MMP activity that spans from days to weeks or longer, affects many cells and cell types over large areas and permits broad access of MMPs to potential proteolytic targets that they may not normally encounter under non-pathophysiological conditions 5, 129 . In the future, it will therefore be crucial to precisely define the regulatory mechanisms that govern focal release, localization, activation and termination of perisynaptic MMP activity, as these become overridden and dysregulated under conditions of injury or disease, leading to aberrant proteolytic processing of synaptic molecules such as NR1 (REFS 130, 131) . A thorough characterization of the regulatory mechanisms that govern MMP activity at the synapse will also serve the design of therapeutic strategies aiming to harness the adaptive roles of MMPs as molecular drivers of synaptic circuit remodelling to promote restoration and repair of damaged brain circuits, while at the same time diminishing the deleterious effects of these molecules that could impede recovery of synaptic function following injury 132 .
Another area of future research will be to see whether other metalloproteinases have functional roles in synaptic structural and behavioural plasticity. Pursuing this question is potentially daunting because of the sheer number of MMPs and other metalloproteinases and the relative lack of reliable reagents to detect them. However, one potential strategy to identify families of metalloproteinases whose proteolytic activity is regulated by plasticity-inducing stimuli is to use MMP active site-directed chemical probes 133 in a high-throughput proteomic screen for plasticity-regulated metalloproteinases, akin to how such probes have been used to identify and distinguish metalloproteinases that are active in certain cancers 134 . Relatedly, another limitation -both experimentally and therapeutically -is the lack of MMP-specific inhibitors. It is already known that different MMPs have distinct cell-type expression patterns, react differently to synaptic stimulation, affect synaptic structural and functional plasticity differently, and exert different pathophysiological effects. Therefore, the need for advancing the development of MMP type-specific inhibitors is self-evident. The formidable obstacle to the development of MMP-specific small-molecule antagonists of the catalytic site is the high structural homology across MMPs and other metzincins in this region. However, recent advances in next-generation small-molecule inhibitors have been described that target exosites or other allosteric regions 135 , and these strategies may prove effective in overcoming the barriers to producing MMP-specific antagonists.
